Quick answer: Four companies make the prescription continuous glucose monitors (CGMs) sold in the US today: Abbott (FreeStyle Libre), Dexcom (G7), MiniMed (the Medtronic diabetes business, with Simplera Sync and Instinct) and Senseonics (the implantable Eversense 365). Abbott and Dexcom sell the large majority of sensors. Over the counter, you’ll also find Dexcom Stelo, Abbott Lingo and Biolinq Shine.
One detail most lists miss: MiniMed’s Instinct sensor is built by Abbott. So when you trace every US sensor back to the factory, the market is even more concentrated than the brand names suggest.
If you’re searching for continuous glucose monitoring companies, you probably want one of two things. Either you’re a patient comparing brands, or you run a practice, health system or care program and need to know which devices you’ll be supporting. This guide covers both, with a heavier lean toward the second group.
We’ll go company by company, then compare every FDA-cleared device in one table. After that come Medicare coverage, the billing codes and a short list of companies that aren’t cleared in the US yet. Everything here was checked against company filings, FDA announcements and CMS documents in November 2026.
Table of Contents
A CGM is a small sensor worn on the skin (or, in one case, under it) that reads glucose in the fluid between your cells every few minutes. It sends those readings to a phone, a reader or an insulin pump. A fingerstick meter gives you one number at one moment; a CGM gives you the whole curve, including the overnight lows and after-meal spikes a fingerstick misses.
Here are the companies with a CGM that the FDA has cleared or approved for sale in the US, as of November 2026:
| Company | Headquarters | US products (2026) | Prescription or OTC |
|---|---|---|---|
| Abbott | Abbott Park, Illinois | FreeStyle Libre 2 Plus, FreeStyle Libre 3 Plus, Libre Duo (glucose + ketone), Lingo, Libre Rio | Both |
| Dexcom | San Diego, California | Dexcom G7, G7 15 Day, Stelo | Both |
| MiniMed (majority-owned by Medtronic) | Northridge, California | Simplera Sync, Instinct (made by Abbott), Guardian 4 | Prescription, sold with MiniMed pumps |
| Senseonics | Germantown, Maryland | Eversense 365 (implanted, one year) | Prescription |
| Biolinq | San Diego, California | Biolinq Shine (intradermal, needle-free) | Type 2 diabetes, not on insulin |
That’s a short list for a market worth well over $12 billion a year. Medical sensors are hard to make at scale, and the FDA’s iCGM standard (the accuracy bar a CGM must clear to drive insulin pumps) keeps the barrier high. Several well-funded companies have tried and pulled their US filings, which we cover further down.
Abbott is the largest CGM company in the world by revenue. Its FreeStyle Libre line started in 2014 as a “flash” sensor you had to scan with a reader; today’s Libre sensors stream readings to a phone automatically, like every other modern CGM.
What Abbott sells in the US:
Abbott also builds the Instinct sensor that MiniMed sells with its 780G pump. That partnership was announced in 2024 and the product launched in the US in late 2025. It means Abbott sensor technology now sits inside three different brands.
Data platform: clinics see patient data in LibreView, a free web portal. Patients use the FreeStyle Libre app or Lingo app.
What to know before you standardize on it: in November 2025, Abbott issued a correction for about 3 million Libre 3 and Libre 3 Plus sensors in the US that could read falsely low. As of November 14, 2025, the company had reported 736 serious injuries and seven deaths linked to the problem. None of the deaths happened in the US, according to MedTech Dive’s report on the FDA early alert. Abbott traced it to a single production line and says it’s fixed. If you have patients on Libre 3 sensors, it’s worth checking their lot numbers against Abbott’s list.
Dexcom has done one thing for 25 years: CGMs. It made the first real-time CGM approved for insulin dosing without a fingerstick, and it’s the sensor most US insulin pumps were built around. Dexcom reported $4.66 billion in 2025 revenue, up 16%, and about 3.5 million users worldwide (not counting Stelo), per its 2025 annual report to shareholders.
What Dexcom sells in the US:
Data platform: clinics use Dexcom Clarity. Dexcom also runs a public developer API, which makes it one of the easier sensors for third-party platforms to pull data from with patient consent.
What to know before you standardize on it: in March 2025 the FDA sent Dexcom a warning letter over a change to a sensor component the agency said made some G7 sensors less accurate. Dexcom disputed the finding and no sensor recall was required. A separate Class I recall that year covered some G7 receivers (the handheld display, not the sensor).
Supporting patients on more than one CGM brand? HealthArc brings CGM data into the same dashboard as blood pressure, weight and medication adherence, so your care team checks one screen instead of three manufacturer portals. Book a demo to see it with your own patient mix.
If you’ve been wondering whether Medtronic still makes CGMs: yes, but under a new name. Medtronic moved its diabetes business into a separate company called MiniMed, which went public on Nasdaq (ticker MMED) on March 9, 2026. Medtronic still owned about 90% of the shares after the IPO and has said it plans to finish the separation.
MiniMed’s CGM strategy is different from Abbott’s and Dexcom’s. Its sensors are sold mainly as part of a pump system, the MiniMed 780G, rather than as stand-alone products.
Data platform: clinics use CareLink, which shows pump and sensor data together.
What to know: MiniMed’s own IPO filing warned that Simplera manufacturing was scaling more slowly than planned and that the company wasn’t sure it could make the sensor profitably, as MedTech Dive reported. That’s probably why it partnered with Abbott on Instinct. For a practice, it means MiniMed patients may arrive on either sensor, and both report into CareLink.
Senseonics makes the only long-term implantable CGM in the US. A clinician places the Eversense sensor just under the skin of the upper arm in a short in-office procedure, and it stays there for up to a year. The patient wears a small removable transmitter over the spot, which also vibrates for high and low alerts.
The current model, Eversense 365, was approved by the FDA in September 2024 for adults 18 and older. It needs one fingerstick calibration a week, which is more than the zero most patch sensors need. In return, the patient gets far fewer sensor changes: one insertion a year versus 24 to 36 for a 10- or 15-day sensor.
Who it suits: people who react to sensor adhesives, people who hate frequent insertions, and active patients who knock patch sensors off. Senseonics and Beta Bionics have said they plan to connect Eversense 365 with the iLet pump by the end of 2026. Its market share is small (under 2% by most estimates), and every insertion and removal needs a trained clinician, so it’s more of a specialty option than a first-line one.
Biolinq is the newest name on this list. Its Shine sensor uses a grid of tiny microsensors that sit up to 20 times shallower in the skin than a standard CGM filament, so there’s no introducer needle at all. The FDA granted it De Novo classification on September 23, 2025 for adults with type 2 diabetes who don’t use insulin.
Shine works differently from the others. It doesn’t show glucose numbers on a phone; a small LED on the sensor glows blue when glucose is in range and yellow when it’s high. It also tracks activity and sleep. That makes it a behavior-change tool, not something you’d use to dose insulin.
This table puts every current US sensor in one place. Wear time is the labeled maximum; real-world wear is often a little shorter, especially in children.
| Device | Company | Wear time | Ages | Rx or OTC | Best fit |
|---|---|---|---|---|---|
| FreeStyle Libre 3 Plus | Abbott | 15 days | 2+ | Rx | Insulin users, AID pumps, Medicare patients |
| FreeStyle Libre 2 Plus | Abbott | 15 days | 2+ | Rx | Insulin users, AID pumps |
| Libre Duo 10 Day | Abbott | 10 days | 2+ | Rx | Type 1 and pump users who need ketone alerts |
| Dexcom G7 | Dexcom | 10 days + 12 h grace | 2+ | Rx | Insulin users, AID pumps, children |
| Dexcom G7 15 Day | Dexcom | 15 days + 12 h grace | 18+ | Rx | Adults who want fewer sensor changes |
| Simplera Sync | MiniMed | 7 days | MiniMed 780G users | Rx | MiniMed pump users |
| Instinct (by Abbott) | MiniMed | 15 days | MiniMed 780G users | Rx | MiniMed pump users who want longer wear |
| Eversense 365 | Senseonics | 1 year (implanted) | 18+ | Rx | Adhesive allergy, very active patients |
| Stelo | Dexcom | 15 days | 2+ | OTC | Type 2 or prediabetes, not on insulin |
| Lingo | Abbott | 14 days | 18+ | OTC | Wellness and metabolic tracking |
| Libre Rio | Abbott | About 2 weeks | 18+ | OTC | Type 2, not on insulin |
| Biolinq Shine | Biolinq | Multi-day patch | 18+ | See label | Type 2, not on insulin, needle-averse |
A word on accuracy. Every company publishes a MARD, but each number comes from that company’s own study, with its own patients and its own reference method. A 0.3-point gap between two brands from two different studies doesn’t tell you much. For prescription sensors, the more useful question is whether the device meets the FDA’s iCGM standard; all the Abbott, Dexcom and Eversense prescription sensors above do.
Abbott, by a clear margin. Abbott’s CGM sales grew 17% in 2025 to more than $7.5 billion, the third straight year the business added over $1 billion in sales, according to coverage of its full-year 2025 results. Dexcom is second at $4.66 billion. MiniMed’s CGM revenue is much smaller, because its sensors mostly ship with its own pumps.
The ranking flips depending on how you count. Abbott sells more sensors worldwide, helped by lower prices and big volumes in Europe. Dexcom has historically been stronger with US insulin-pump users and in pediatrics. Market-research firms publish share figures ranging from 30% to 58% for Abbott alone, which tells you how much those estimates depend on method. Company filings are the numbers to trust.
Yes. Since 2024, you can buy a CGM online or at a pharmacy without seeing a doctor: Dexcom Stelo, Abbott Lingo and Abbott Libre Rio. All of them are for people who don’t use insulin. They’re cleared to show trends and help with diet, exercise and sleep habits, not to make treatment decisions.
OTC sensors are paid out of pocket or through an HSA or FSA. Medicare doesn’t cover them, and most commercial plans don’t either.
For practices, OTC sensors raise a new question: what do you do when a patient brings you two weeks of Stelo data? The ADA’s 2026 Standards of Care now recommend CGM for adults with type 2 diabetes on any glucose-lowering treatment, including people who never take insulin. In the CONNECT trial presented in June 2026, adults with type 2 diabetes not on insulin who used a CGM lowered their A1C by 0.9 percentage points more than routine care over six months. More of your non-insulin patients will show up with sensor data, whether you prescribed it or not.
Plenty of companies sell CGMs in Europe or Asia that you can’t legally buy in the US. A few worth tracking:
One warning that belongs in any guide like this: no smartwatch or smart ring can measure blood glucose. The FDA issued a safety communication in February 2024 telling people not to use watches or rings that claim to read glucose without piercing the skin. None are FDA-authorized. If a patient tells you their watch shows their sugar, it’s either pulling data from a real CGM or it’s guessing.
Medicare covers prescription CGMs from Abbott, Dexcom, MiniMed and Senseonics under Part B as durable medical equipment (DME). Coverage follows local coverage determination L33822, which the DME contractors updated in April 2023. A patient qualifies when all of these are true:
After that, the patient needs a follow-up visit every six months to keep coverage, where the clinician reviews CGM use and the treatment plan. That’s the step practices most often miss in the chart. OTC sensors aren’t covered at all.
Medicare Advantage plans follow the same rules but can add prior authorization or prefer certain brands. For example, Blue Cross NC’s 2026 Medicare criteria name Dexcom and FreeStyle Libre as preferred and require prior authorization for others. Check the plan’s list before you write the order, because that’s often what decides the brand.
Here’s the part most “best CGM” lists get wrong. If you run a diabetes or remote monitoring program, you usually don’t get to pick one CGM company. The patient’s insurance formulary, their insulin pump and their own preference decide it for you. A practice with 300 CGM patients will almost always have Libre, Dexcom and some MiniMed users at the same time.
So the better question is how you’ll handle all of them. These are the checks we’d run:
The data question is where most programs stall. Three portals means three logins, three report formats and nothing in the EHR unless someone copies it over. Patients’ overnight lows show up in the portal, but no one looks until the next visit. It’s the question practice managers ask us most when they add CGM patients to a remote monitoring program. That’s why HealthArc pulls CGM readings into the same care-team view as every other vital, with threshold alerts and documentation that flows to your EHR.
If your diabetes patients are on fingerstick meters rather than sensors, the same program can run on a cellular glucometer. Our guide to remote patient monitoring for diabetes covers how the two fit together.
CGM has its own three CPT codes, separate from the standard remote patient monitoring (RPM) codes. Here are the 2026 Medicare national non-facility rates, calculated from CMS’s RVU26D file and the $33.4009 conversion factor:
| CPT code | What it covers | Total RVUs | 2026 national rate |
|---|---|---|---|
| 95249 | Patient-owned CGM: startup, hookup, training and printout. Minimum 72 hours of data. Once per period the patient owns the device. | 2.09 | $69.81 |
| 95250 | Practice-owned CGM: sensor placement, hookup, calibration, training and printout. Minimum 72 hours. No more than once a month. | 4.57 | $152.64 |
| 95251 | Analysis, interpretation and report by a physician or other qualified clinician. No more than once per 30 days. | 1.05 | $35.07 |
Your actual payment will differ by locality, and the CY2027 fee schedule lowers the conversion factor to $32.6286 on January 1. The CPT code library has the full RPM and care-management code set.
A common question is whether you can bill RPM device-supply code 99454 for a CGM. If Medicare already pays a DME supplier for the patient’s sensors, billing 99454 for the same device is generally treated as paying twice for the device, so most compliance teams don’t do it. Whether RPM management time (99457 and 99458) or chronic care management fits alongside CGM depends on how your program is set up. Check with your Medicare Administrative Contractor before you build a workflow around it.
A few changes are already scheduled, and they’ll affect which companies your patients use:
The bigger shift is who wears a CGM. With the ADA now recommending sensors for type 2 patients who don’t use insulin, and OTC options for anyone over age 2, CGM data is moving from endocrinology into everyday primary care. Practices that set up their data workflow now will handle that growth much more easily than those still logging into separate portals.
Building a diabetes program across every CGM brand? HealthArc runs RPM and care management for practices, FQHCs and health systems, with CGM and glucometer data in one place and a clinical team that reviews readings between visits. Book a demo.
Abbott (FreeStyle Libre) and Dexcom (G7) are the two largest by far. MiniMed, the Medtronic diabetes business, sells CGMs with its insulin pumps, and Senseonics makes the only implantable CGM, Eversense 365. Biolinq is the newest FDA-cleared company, with a needle-free sensor for type 2 diabetes.
There’s no clean answer, because each company reports accuracy (MARD) from its own study. Dexcom reports 8.0% for the G7 15 Day, and Abbott’s Libre 3 Plus is in a similar range. All current prescription sensors from Abbott, Dexcom and Senseonics meet the FDA’s iCGM accuracy standard, and that tells you more than a small MARD difference does.
Yes, through MiniMed, the diabetes company Medtronic took public in March 2026. MiniMed sells the Simplera Sync sensor and the Abbott-built Instinct sensor, both for its MiniMed 780G insulin pump.
Yes, for people with diabetes who use insulin or have a history of problematic low blood sugar. They need an in-person or telehealth visit within six months before the order and a follow-up visit every six months after. OTC sensors like Stelo and Lingo aren’t covered.
Yes. Dexcom Stelo, Abbott Lingo and Abbott Libre Rio are sold over the counter for people who don’t use insulin. Stelo is cleared for ages 2 and up; Lingo and Libre Rio are for adults.
The best one is whichever your patients’ insurance and pumps support, because you’ll rarely get to standardize on one brand. The clinic’s real job is getting readings from Libre, Dexcom and MiniMed sensors into one view with alerts, instead of checking three portals. Dexcom’s public API and Abbott’s LibreView both support third-party platforms with patient consent.
CGM has its own codes: 95249 for patient-owned devices, 95250 for practice-owned devices and 95251 for interpretation. Billing RPM device code 99454 for a CGM Medicare already pays for as DME is generally treated as double payment. Confirm any RPM time billing with your MAC first.
No. The FDA has warned that no smartwatch or smart ring can measure blood glucose on its own, and none are authorized to do so. A watch can only display readings from a real CGM paired to it.
This article is general information for patients and healthcare organizations, not medical or billing advice. Device indications, coverage rules and payment rates change, so check the manufacturer’s current labeling, your payer’s policy and your MAC before making clinical or billing decisions.
See how HealthArc runs RPM, CCM and seven more CMS programs — the platform, the devices and the clinical team — on a single demo.